Shares of Amicus Therapeutics (FOLD) have gained 12.9% over the past four weeks to close the last trading session at $6.83, ...

Amicus Therapeutics (FOLD) could be a solid choice for investors given the company's remarkably improving earnings outlook.

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...

Amicus Therapeutics (NASDAQ:FOLD) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

Amicus Therapeutics reported a remarkable 2024 with total revenue reaching approximately $528.5 million, reflecting a 32% year-over-year growth, driven mainly by strong demand for its products ...

Despite the bear market, Amicus Therapeutics is enjoying aggressive sales growth for its lead medicine, Galafold, for Fabry. By mid-year, you are most likely to see another approval, that is, AT ...

Amicus estimates the current U.S. Pompe market represents a more than $500 million opportunity; $1.2 billion globally. Pombiliti and Opfolda received European Union approval earlier this year.

For the quarter, Amicus generated $2.1 million in product revenue, which is up from zilch last year, when it had no products on pharmacy shelves, and a net loss of $46.7 million, or $0.33 per ...